The overall purpose of the Biostatistics Core ofthe UAB/UMN SPORE in Pancreatic Cancer is to contribute to the science and operation of the SPORE by participating fully in its activities. This includes participation in project development from the outset. The Core, is a joint activity of the Biostatistics and Informatics Core of University of Minnesota Cancer Center and the Biostatistics and Bioinformatics Shared Facility of the Comprehensive Cancer Center of the University of Alabama. Specifically, we will provide biostatistical consultation and support by assisting in experimental design and the collection, visualization, analysis, quantitative modeling, interpretation, and publication for all SPORE projects and cores;develop new or adapt existing biostatistical methods as needed and appropriate, provide assistance with the identification and solution of complex database tasks arising in the course of SPORE activities particularly for the tissue and clinical cores, develop new or adapt existing data management techniques and systems as needed, implement appropriate Quality Assurance (QA) plans for all data collection activities, and work closely with the SPORE leaders to implement the Developmental Research Program and the Career Development Program. The Core includes a team of 8 faculty statisticians from the two institutions who have developed a productive management plan to coordinate activities and to handle SPORE data and analyses with state of the art approaches. Two lead statisticians are designated for each project and a member also will work with the other two Cores and with the projects in the Developmental Research Program and the Career Development Program. One member will serve on the mentorship team proposed for fellows selected for this program. Databases systems will meet the appropriate regulatory requirements and will be based at UAB in the Division of Preventive Medicine In a highly secure system with full redundancy in back ups.
Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129 |
Tiriac, Herve; Bucobo, Juan Carlos; Tzimas, Demetrios et al. (2018) Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc 87:1474-1480 |
Contreras, Carlo M; Lin, Chee Paul; Oster, Robert A et al. (2017) Increased pancreatic cancer survival with greater lymph node retrieval in the National Cancer Data Base. Am J Surg 214:442-449 |
Roe, Jae-Seok; Hwang, Chang-Il; Somerville, Tim D D et al. (2017) Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 170:875-888.e20 |
Chio, Iok In Christine; Tuveson, David A (2017) ROS in Cancer: The Burning Question. Trends Mol Med 23:411-429 |
Li, Yonghe; Oliver, Patsy G; Lu, Wenyan et al. (2017) SRI36160 is a specific inhibitor of Wnt/?-catenin signaling in human pancreatic and colorectal cancer cells. Cancer Lett 389:41-48 |
Feigin, Michael E; Garvin, Tyler; Bailey, Peter et al. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet 49:825-833 |
Roberts, Allison M; Miyamoto, David K; Huffman, Tucker R et al. (2017) Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target. ACS Chem Biol 12:899-904 |
Carlson, Marjorie; Watson, Adrienne L; Anderson, Leah et al. (2017) Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors. J Biomed Opt 22:1-9 |
Öhlund, Daniel; Handly-Santana, Abram; Biffi, Giulia et al. (2017) Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214:579-596 |
Showing the most recent 10 out of 173 publications